BYSI News

BeyondSpring, which is developing a cancer therapy to combat the loss of white blood cells, raised $3 million by offering 0.17 million shares at $20, the low end of the range of $20 to $22. BeyondSpring plans to list on the Nasdaq under the symbol BYSI. Rodman & Renshaw acted as a lead manager on the deal....read more

BeyondSpring, which is developing a cancer therapy to combat the loss of white blood cells, lowered the proposed deal size for its upcoming IPO on Wednesday. The New York, NY-based company now plans to raise $3 million by offering 0.1 million shares at a price range of $20 to $22. The company had previously filed to offer 0.5 million shares at a range of $20 to $22. At the...read more

BeyondSpring, which is developing a cancer therapy to combat the loss of white blood cells, announced terms for a $10 million IPO and $51 million concurrent private placement on Tuesday. The company originally filed for a $100 million offering in November 2016. The New York, NY-based company plans to raise $10 million by offering 0.5 million shares at a price range of $20...read more

Sandwiched between the election and Thanksgiving, the US IPO market had another slow week for new offerings. Meanwhile, recent news and a string of initial filings signals that companies are preparing for IPOs in December and early 2017. Those plans are supported by the S&P 500's two-week rally of +4.7%; during the same time, year-to-date performance for 2016 IPOs has...read more